Jazz Pharmaceuticals PLC $JAZZ Shares Acquired by Alliancebernstein L.P.

Key Points

• Alliancebernstein L.P. increased its holdings in Jazz Pharmaceuticals PLC by 33.5%, owning 117,949 shares valued at approximately $14.6 million at the end of the first quarter.
• Research analysts have a positive outlook on Jazz Pharmaceuticals, with an average target price of $178.67 and 14 analysts rating it as a "Buy."
• Jazz Pharmaceuticals reported a miss in earnings with a loss of ($8.25) per share, despite revenue of $1.05 billion being in line with expectations.

Alliancebernstein L.P. increased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 33.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 117,949 shares of the specialty pharmaceutical company's stock after buying an additional 29,578 shares during the period. Alliancebernstein L.P. owned about 0.19% of Jazz Pharmaceuticals worth $14,643,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals during the first quarter worth about $25,000. Elequin Capital LP boosted its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after buying an additional 183 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 85.6% in the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after purchasing an additional 119 shares in the last quarter. Picton Mahoney Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Finally, Spire Wealth Management lifted its holdings in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director owned 429,973 shares of the company's stock, valued at $55,303,127.26. This represents a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on JAZZ. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. The Goldman Sachs Group upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday, August 29th. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Morgan Stanley upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a report on Thursday, August 28th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $178.67.

Jazz Pharmaceuticals Trading Up 2.4%

NASDAQ:JAZZ traded up $3.00 during trading hours on Wednesday, reaching $129.54. 775,697 shares of the company were exchanged, compared to its average volume of 667,460. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The stock has a 50 day simple moving average of $119.65 and a 200 day simple moving average of $116.39. The firm has a market cap of $7.86 billion, a price-to-earnings ratio of -19.25, a PEG ratio of 7.85 and a beta of 0.24. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the company earned $5.30 EPS. Jazz Pharmaceuticals's revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.